View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
For the first time, a drug therapy has been shown to slow the rate of lung function loss in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Treatment with salmeterol (a long-acting inhaled beta2-agonist) and fluticasone propionate (an inhaled corticosteroid), either alone or together, significantly slowed the rate of decline in a large, randomized, double-blind, placebo-controlled trial spanning 42 countries.
The study, called TORCH (Towards a Revolution in COPD Health), involved more than 6,000 patients with moderate to severe COPD. The patients received salmeterol, fluticasone propionate, the two in combination, or a placebo. Researchers measured forced expiratory volume in 1 second (FEV1) at baseline and every 24 weeks after the start of therapy to determine the rate of decline in FEV1.
The rate of FEV1 decline was slowest in patients taking both drugs and fastest in those taking a placebo. The effect of treatment on FEV1 decline was similar regardless of smoking status, sex, age, baseline FEV1, ethnicity, body mass index, or previous exacerbations, researchers report. Until now, smoking cessation was the only treatment shown to slow the rate of decline in FEV1.
Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178(4):332-338; Suissa S.
Medications to modify lung function decline in chronic obstructive pulmonary disease: Some hopeful signs. Am J Resp Crit Care Med. 2008;178(4):322-323.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top